Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2025Diabetes Metabolic Syndrome and ObesityOpen Access

Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss in Patients with Obesity or Overweight: A Systematic Review

View Full Paper
Ask AI
Bookmark
Share

Authors

ZXZeyu XieShenzhen Luohu People's HospitalZLZhuoru LiangJinan UniversityYXYuanyun XieUniversity of Central Florida

Discussion

Loading...

Member takes

Implication

Systematic review reveals safety differences in GLP-1/GIP agonists versus GLP-1 receptor agonists for weight loss in patients with obesity, highlighting varying adverse events.

Key Points

  • Tirzepatide showed superior safety for neoplasms compared to liraglutide and semaglutide, reducing certain adverse events.
  • Adults treated with liraglutide experienced a significantly higher rate of overall adverse events, further impacting treatment choices.
  • Network meta-analysis of 19 RCTs revealed varying risks of serious adverse events, with tirzepatide linked to greater severe hypoglycemia.
  • Sensitivity analyses confirmed the robustness of the results and indicated no publication bias affecting the findings.

Cite This Study

Xie et al. (2025) studied this question.

synapsesocial.com/papers/68af2690cf1dd9ea359e2147https://doi.org/10.2147/dmso.s537229
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched one closely related paper. Consider it for comparative context:

  1. 1Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial2022 · 865 citations